➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
McKesson
Mallinckrodt
Colorcon
Harvard Business School

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,696,493


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,696,493 protect, and when does it expire?

Patent 6,696,493 protects CARNITOR and is included in one NDA.

This patent has four patent family members in four countries.

Summary for Patent: 6,696,493
Title: Treating chronic uremic patients undergoing periodic dialysis
Abstract:The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Inventor(s): Cavazza; Claudio (Rome, IT)
Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:10/189,451
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,696,493

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 AP RX Yes Yes ⤷  Try it Free ⤷  Try it Free USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,696,493

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 3050201 ⤷  Try it Free
Canada 2381187 ⤷  Try it Free
European Patent Office 1257266 ⤷  Try it Free
World Intellectual Property Organization (WIPO) 0152836 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Dow
Moodys
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.